ASTMH Annual Meeting 2021

blog
ASTMH Annual Meeting 2021 Blog / All Blog Posts / How we can treat severe malaria cases in the U.S.

How we can treat severe malaria cases in the U.S.

By: Joanne Morrison, University of Maryland School of Medicine

Photo: Malaria, Global Health & Infectious Diseases 11.22.19

Increased global travel gives rise to malaria cases in the U.S. and a need for better access to intravenous treatment for the most serious cases. While the vast majority of the more than 200 million cases of malaria worldwide occur in sub-Saharan Africa and South Asia, the U.S. sees more than 1,500 cases a year and currently there is limited access to an intravenously-administered (IV) drug needed for the most serious cases. 


Mark Travassos, MD, Assistant Professor of Pediatrics at the University of Maryland School of Medicine (UMSOM), warns that this treatment for severe cases of malaria is no longer widely available in IV form in the U.S. “Severe malaria is a medical emergency that requires immediate treatment with IV medication to reduce the risk of death,” said Dr. Travassos, a pediatric infectious diseases specialist and malaria expert in UMSOM’s Malaria Research Program. Dr. Travassos, a pediatric infectious disease specialist, spoke about his malaria research being conducted in Mali at TropMed19. 


Without a broad supply of the IV drug, physicians treating serious malaria cases must on a case-by-case basis request IV artesunate, a non-U.S. Food and Drug Administration-approved drug for severe malaria that is only available from the Centers for Disease Control and Prevention (CDC) at ten different airports in the U.S. The CDC will then ship the drug to the airport closest to a requesting hospital. Delivery times will take on average eight hours, but they could be as long as 24 hours.


“This raises serious concerns,” said Dr. Travassos, adding that the CDC’s recommendation that a physician treat a patient with oral medication while waiting for IV treatment to arrive does not meet the standard of care for severe malaria and will not reduce parasite replication in the blood as rapidly as an effective intravenous medication.


At the hospital level, Dr. Travassos recommends a protocol that addresses potential delays in diagnosis and treatment of malaria, with anticipation of different scenarios. At triage, patients should be questioned about recent travel outside the country. Those who are febrile and have recently traveled to malaria-endemic regions should immediately have a rapid diagnostic test for malaria, and a thick and thin blood smear should be sent for an immediate reading, Dr. Travassos recommends.


Share this story

Related Posts

Global Health 11.20.20
Predicting the Future: The Importance and Limitations of Outbreak Science

By: Rebecca Mandt, Phd Candidate, Harvard University

Global Health & Infectious Diseases 11.20.20
Vector-borne diseases eradication: being one step ahead with modeling

By: Maria Luísa Simões, Phd, Johns Hopkins University

See all posts